Related resources and publications
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
Immuno-oncolology models
The humanized CD28 model, developed by Knockin at the mouse CD28 locus, expresses a chimeric CD28 with a human extracellular and murine transmembrane and intracellular domains. The design also gives access to CD28 conditional Knockout mice.
hCD28 and mCD28 expression on freshly isolated splenocytes on (A) CD8+ (viable, CD3+CD8+) T cells, (B) conventional CD4+ (viable, CD3+CD4+Foxp3-), and (C) Tregs (viable, CD3+CD4+CD25+Foxp3+).
Isolated T cells were labeled with CTV and activated with αCD3 and soluble mouse or human αCD28 for 4 days. Representative FACS bar graphs indicating (A) CD25 expression as a marker of activation, and (B) CTV dilution (as a measure of proliferation) gated on live T cells. Results are expressed as mean±SD. Unpaired T test analyses (**p<0.01, ***p<0.001).
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
Immuno-oncolology models
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate